XENON PHARMACEUTICALS INC. (XENE) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
XENON PHARMACEUTICALS INC. (XENE) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$45.01 MLiabilities$53.38 MNon-current liabilities$8.37 MEquity$1.24 BCurrent assets$945.87 MGross equity(calculated)$2.70 BAssets$1.30 BNon-current assets$349.90 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSMarketable securities (note 5)Cash and cash equivalentsPrepaid expenses and other current assetsOther receivablesMarketable securities, long-term (note 5)Deferred tax assetsPrepaid expenses, long-termProperty, plant and equipment, netOperating lease right-of-use asset, net (note 6)Accounts payable and accrued liabilities (note 7)Operating lease liability (note 6)Operating lease liability, long-term (note 6)Other liabilities, long-termCommon shares, without par value; unlimited shares authorized; issued and outstanding: 96,752,884 (December 31, 2025 - 80,010,790) (note 8)Additional paid-in capitalCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Accumulated deficitAccumulated other comprehensive income (loss)Current liabilitiesCurrent liabilities$45.01 MAccounts payable and accrued liabilities (note 7)Accounts payable and accrued liabilities (note 7)$43.67 MLiabilitiesLiabilities$53.38 MOperating lease liability (note 6)Operating lease liability (note 6)$1.34 MNon-current liabilitiesNon-current liabilities$8.37 MOperating lease liability, long-term (note 6)Operating lease liability, long-term (note 6)$5.08 MEquityEquity$1.24 BCurrent assetsCurrent assets$945.87 MOther liabilities, long-termOther liabilities, long-term$3.29 MGross equity (calculated)Gross equity(calculated)$2.70 BMarketable securities (note 5)Marketable securities (note 5)$811.16 MAssetsAssets$1.30 BCash and cash equivalentsCash and cash equivalents$119.53 MPrepaid expenses and other current assetsPrepaid expenses and other current assets$13.55 MOther receivablesOther receivables$1.63 MCommon shares, without par value; unlimited shares authorized; issued and outstanding: 96,752,884 (December 31, 2025 - 80,010,790) (note 8)Common shares, without par valueand unlimited shares authorized$2.43 BMarketable securities, long-term (note 5)Marketable securities, long-term (note 5)$314.41 MNon-current assetsNon-current assets$349.90 MDeferred tax assetsDeferred tax assets$14.36 MPrepaid expenses, long-termPrepaid expenses, long-term$7.97 MProperty, plant and equipment, netProperty, plant and equipment, net$7.77 MOperating lease right-of-use asset, net (note 6)Operating lease right-of-use asset, net (note 6)$5.39 MAdditional paid-in capitalAdditional paid-in capital$276.85 MAccumulated deficitAccumulated deficit−$1.46 BAccumulated other comprehensive income (loss)Accumulated other comprehensive income (loss)−$2.66 M
Chart details

XENON PHARMACEUTICALS INC. (XENE) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
1,295,772,000 US dollars
Current assets
945,868,000 US dollars
Non-current assets
349,904,000 US dollars
Liabilities
53,376,000 US dollars
Current liabilities
45,009,000 US dollars
Non-current liabilities
8,367,000 US dollars
Equity
1,242,396,000 US dollars
Marketable securities (note 5)
811,159,000 US dollars
Cash and cash equivalents
119,527,000 US dollars
Prepaid expenses and other current assets
13,553,000 US dollars
Other receivables
1,629,000 US dollars
Marketable securities, long-term (note 5)
314,411,000 US dollars
Deferred tax assets
14,361,000 US dollars
Prepaid expenses, long-term
7,973,000 US dollars
Property, plant and equipment, net
7,774,000 US dollars
Operating lease right-of-use asset, net (note 6)
5,385,000 US dollars
Accounts payable and accrued liabilities (note 7)
43,671,000 US dollars
Operating lease liability (note 6)
1,338,000 US dollars
Operating lease liability, long-term (note 6)
5,080,000 US dollars
Other liabilities, long-term
3,287,000 US dollars
Common shares, without par value; unlimited shares authorized; issued and outstanding: 96,752,884 (December 31, 2025 - 80,010,790) (note 8)
2,426,619,000 US dollars
Additional paid-in capital
276,851,000 US dollars
Accumulated deficit
negative 1,458,418,000 US dollars
Accumulated other comprehensive income (loss)
negative 2,656,000 US dollars
Gross equity (calculated)
2,703,470,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
XENON PHARMACEUTICALS INC. (XENE) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!